United States

People: Infinity Pharmaceuticals Inc (INFI.O)

INFI.O on Nasdaq

21 Oct 2016
Change (% chg)

$-0.02 (-1.45%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Perkins, Adelene 

Ms. Adelene Q. Perkins is Chairman of the Board, President, Chief Executive Officer of Infinity Pharmaceuticals Inc. She has served as our President and Chief Executive Officer since January 2010, President and Chief Business Officer from October 2008 through December 2009 and as our Executive Vice President and Chief Business Officer between September 2006 and October 2008. Ms. Perkins served as Executive Vice President of IPI from February 2006 until its merger with DPI in September 2006 and Chief Business Officer of IPI from June 2002 until the DPI merger. Prior to joining IPI, Ms. Perkins served as Vice President of Business and Corporate Development of TransForm Pharmaceuticals, Inc., a private pharmaceutical company, from 2000 to 2002. From 1992 to 1999, Ms. Perkins held various positions at Genetics Institute, most recently serving as Vice President of Emerging Business and General Manager of the DiscoverEase® business unit. Ms. Perkins has served as a director of the Biotechnology Industry Organization since 2012, a director of Project Hope, a not-for-profit social services company since 2013, a director of the Massachusetts Life Sciences Center, a quasi-public agency of the Commonwealth of Massachusetts, since 2014, a director of the Massachusetts Biotechnology Council, a not-for-profit organization, since 2014, and a director of Padlock Therapeutics, a privately held biopharmaceutical company since 2015. From 1985 to 1992, Ms. Perkins held a variety of positions at Bain & Company, a strategy consulting firm. Ms. Perkins received a B.S. in Chemical Engineering from Villanova University and an M.B.A. from Harvard Business School.

Basic Compensation

Total Annual Compensation, USD 938,025
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 697,454
Fiscal Year Total, USD 1,635,480

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --